Pixabay / StockSnap / CC0 Public Domain
Shares of Cara Therapeutics Inc. (NASDAQ: CARA), a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.
Before you click the “buy” button, keep two things in mind. First, since Cara has no approved therapies on pharmacy shelves, a failure in any one of its phase trials could wind up pummeling its stock.
While Cuba and the United States are working closely to combat the small country’s ongoing problem with drug trafficking, Cuban officials have said that the legalization of marijuana in nearby countries is actually adding to the trouble, dispelling the prospects of Cuban marijuana legalization.
On June 20, 2017, Battelle, an Ohio-based non-profit research and development organization that has studied tobacco for the past 50 years, announced that it would be expanding its research efforts to include marijuana and opioids.
On June 21, 2017, attorney Jasmine Rand announced that her client, Jawara McIntosh, son of iconic reggae artist Peter Tosh, was beaten into a coma on Feb. 21, 2017, at New Jersey’s Bergen County Jail while serving six months for cannabis-related charges.
